Evidence map›Paper›PMID 42199534›Full record

ReviewJournal of pharmaceutical analysis2026

The role of NRF2 in human cancers: Pre-clinical insights paving the way for clinical trials.

Yi Pei, Jianqiao Yin, Jiamei Liu, Dongze Liu, Qianlong Wu, Xue Cai, Mingming Han, Yu Tian, Liyu Yang, Shengye Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi PeiDepartment of Bone and Soft Tissue Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, China.
Jianqiao YinDepartment of Oncology, Shengjing Hospital, China Medical University, Shenyang, 110004, China.
Jiamei LiuDepartment of Pathology, Shengjing Hospital, China Medical University, Shenyang, 110004, China.
Dongze LiuDepartment of Orthopedics, Shengjing Hospital, China Medical University, Shenyang, 110004, China.
Qianlong WuDepartment of Orthopedics, Shengjing Hospital, China Medical University, Shenyang, 110004, China.
Xue CaiDepartment of Psychosomatic Medicine, The Huizhou Second People's Hospital, Huizhou, Guangdong, 516001, China.
Mingming HanDepartment of Pharmacy and Medical Devices, Shandong Academy of Occupational Health and Occupational Medicine, Occupational Disease Hospital of Shandong First Medical University (Shandong Province Hospital Occupational Disease Hospital), Jinan, 250002, China.
Yu TianSchool of Public Health, Benedictine University, Lisle, IL, 60532, USA.
Liyu YangDepartment of Orthopedics, Shengjing Hospital, China Medical University, Shenyang, 110004, China.
Shengye LiuDepartment of Orthopedics, Shengjing Hospital, China Medical University, Shenyang, 110004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumorigenesis is considered as a complex, multistep process in which genetic mutations play a crucial role. The genetic mutations cause notable changes, not only in the biological behavior of tumor cells but also in their reactions to treatment. Nuclear factor erythroid 2-related factor 2

Indexed as

Anti-cancer compoundsCancer progressionNon-coding RNAsNRF2Targeted therapy

Identifiers

PMID42199534
PMCPMC13199830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.